MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · The American journal of otology · 1996

Use of nimodipine in the medical treatment of Menière's disease: clinical experience.

Lassen L F, Hirsch B E, Kamerer D B

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Nimodipine is a highly lipophilic, centrally acting calcium channel blocker. It is similar in action to flunarizine, which has been studied for use in the medical treatment of Menière's disease.

METHODS

Nimodipine was offered to patients with Menière's disease for whom first-line medical management failed (dietary restrictions and diuretics or vestibular suppressants).

RESULTS

Our preliminary clinical experience using nimodipine in 12 patients with Menière's disease from December 1992 until March 1995 resulted in successful control of vertigo and hearing improvement or stabilization in seven (58%) of 12 patients. When hearing stabilization was not considered, eight (67%) patients had vertigo satisfactorily controlled (AAOO class A, B, or C). The four (33%) patients whose vertigo symptoms persisted despite treatment with nimodipine (AAOO class D) were surgically treated with successful vertigo control. Nimodipine was discontinued in one class D patient because of gastrointestinal intolerance.

CONCLUSIONS

Nimodipine provides an alternative successful means for medical management of Menière's disease.

Для цитирования: Lassen L F, Hirsch B E, Kamerer D B. Use of nimodipine in the medical treatment of Menière's disease: clinical experience.. The American journal of otology. 1996.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.